Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- S-4 Registration of securities issued in business combination transactions
- 10.42 Exhibit 10.42
- 10.43 Exhibit 10.43
- 10.44 Exhibit 10.44
- 10.45 Exhibit 10.45
- 10.49 Exhibit 10.49
- 21.1 Exhibit 21.1
- 23.1 Exhibit 23.1
- 23.2 Exhibit 23.2
- 23.3 Exhibit 23.3
- 99.1 Exhibit 99.1
- 99.2 Exhibit 99.2
- 99.3 Exhibit 99.3
- 99.4 Exhibit 99.4
- EX-FILING FEES Ex-filing Fees
Associated filings
- 2 Nov 23 S-8 POS Registration of securities for employees (post-effective amendment)
- 29 Aug 23 EFFECT Notice of effectiveness
- 28 Aug 23 424B3 Prospectus supplement
- 25 Aug 23 S-4/A Registration of securities issued in business combination transactions (amended)
-
8 Aug 23 S-4 Registration of securities issued in business combination transactions
IMNM similar filings
Filing view
External links
Exhibit 99.3
Consent to be Named as a Director Nominee
In connection with the filing by Immunome, Inc. of the Registration Statement on Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of Immunome, Inc. following the consummation of the merger in the Registration Statement and any and all amendments and supplements thereto. I also consent to the filing of this consent as an exhibit to such Registration Statement and any amendments thereto.
Date: August 2, 2023 | /s/ Isaac Barchas |
Isaac Barchas |